Form 4 for BVS Bioventus Inc.
Accepted 2023-06-20 00:00:00 ET · period of report 2023-06-16 · accession 0001578563-23-000051 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-06-20 | 2023-06-16 | BVS | Ladone Mary Kay | Dir | M - OptEx | $0.00 | +1,813 | 20.3K | +10% | $0 |
| D | 2023-06-20 | 2023-06-16 | BVS | Ladone Mary Kay | Dir | M - OptEx | $0.00 | -1,813 | 1,814 | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2023-06-16 | M | A | 1,813 | $0.00 | 20,274 | D | — | — | |
| 2 | Derivative | Restricted Stock Units | 2023-06-16 | M | D | 1,813 | $0.00 | 1,814 | D | — · — to — | 1,813 Class A Common Stock | (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. (F2) 1,813 RSUs vested on June 16, 2023. The remaining 1,814 RSUs shall vest and become exercisable on June 16, 2024, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. |